Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

A pharmaceutical composition comprising a tumor-suppressive effective amount of rhUG and a pharmaceutically acceptable carrier or diluent.

A method of preventing or treating tumor metastasis by inhibiting fibronectin aggregation and/or deposition comprising administering to a patient in need of such prevention or treatment a fibronectin inhibiting effective amount of rhUG or a fragment or derivative thereof.

A method of stimulating hematopoiesis comprising administering to a patient in need of such stimulation a hematopoiesis stimulating effective amount of rhUG or a fragment or derivative thereof.

A pharmaceutical composition comprising a hematopoiesis stimulating effective amount of rhUG or a fragment or derivative thereof and a pharmaceutically acceptable carrier or diluent.

A method of screening a sample comprising one or more compounds, peptides and/or proteins for uteroglobin structural analogs and/or UG-receptor ligands comprising

• (a) contacting said sample with a purified uteroglobin receptor(s);
• and
• (b) detecting a binding interaction between said receptor(s) and said sample, which binding interaction is indicative of the presence of a uteroglobin structural analog and/or UG-receptor ligand in said sample.

A kit for screening of uteroglobin structural analogs and/or UG-receptor ligands comprising purified uteroglobin receptor(s).

A method of purifying a uteroglobin receptor(s) from a sample comprising

• (a) contacting said sample with rhUG bound to a solid support;
• and
• (b) eluting a purified sample of uteroglobin receptor(s) from said solid support.

A method of preparing reduced rhUG comprising contacting oxidized rhUG with a reducing agent for a time and temperature sufficient to reduce rhUG.

A method of generating antibodies to a uteroglobin receptor(s) comprising immunizing an animal with a purified uteroglobin receptor(s) and isolating antibodies to said receptor(s).